<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2015-385-390</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2109</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Связь уровней цитокинов с активностью заболевания, уровнем аутоантител и деструктивными изменениями суставов при раннем ревматоидном артрите</article-title><trans-title-group xml:lang="en"><trans-title>AN ASSOCIATION OF CYTOKINE LEVELS WITH DISEASE ACTIVITY, AUTOANTIBODY LEVELS, AND JOINT DESTRUCTIVE CHANGES IN EARLY RHEUMATOID ARTHRITIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Авдеева</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Avdeeva</surname><given-names>A. S.</given-names></name></name-alternatives><email xlink:type="simple">9056249400@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новиков</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikov</surname><given-names>A. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Александрова</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Aleksandrova</surname><given-names>E. N.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>Д. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>D. E.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnov</surname><given-names>A. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лучихина</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Luchikhina</surname><given-names>E. L.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E. L.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>10</day><month>09</month><year>2015</year></pub-date><volume>53</volume><issue>4</issue><fpage>385</fpage><lpage>390</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Авдеева А.С., Новиков А.А., Александрова Е.Н., Каратеев Д.Е., Смирнов А.В., Лучихина Е.Л., Насонов Е.Л., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Авдеева А.С., Новиков А.А., Александрова Е.Н., Каратеев Д.Е., Смирнов А.В., Лучихина Е.Л., Насонов Е.Л.</copyright-holder><copyright-holder xml:lang="en">Avdeeva A.S., Novikov A.A., Aleksandrova E.N., Karateev D.E., Smirnov A.V., Luchikhina E.L., Nasonov E.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2109">https://rsp.mediar-press.net/rsp/article/view/2109</self-uri><abstract><p>Цель – оценить взаимосвязь показателей цитокинового профиля с активностью заболевания, уровнем аутоантител, деструктивными изменениями суставов у пациентов с ранним ревматоидным артритом (РА).</p><sec><title>Материал и методы</title><p>Материал и методы. Обследовано 45 больных ранним РА (в том числе 35 женщин), медиана возраста – 53,5 [46; 59,5] года, длительности заболевания – 7,0 [4,0; 11,5] мес, DAS28 – 5,8 [4,9; 6,4]; 91% больных были позитивны по ревматоидному фактору (РФ), 96% – по антителам к циклическому цитруллинированному пептиду. Концентрацию цитокинов в сыворотке крови определяли с помощью мультиплексной технологии хMАР. Для количественной оценки рентгенологических изменений использовался модифицированный метод Sharp.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. В группе больных с высокой активностью заболевания (n=30, DAS28 &gt;5,1) регистрировался более высокой уровень (пг/мл) интерлейкина 6 (ИЛ6) – 62,3 [36,1; 127,5] и IP10 – 6367,8 [3682,7;10691,3], по сравнению с пациентами с умеренной/низкой активностью болезни (n=15; DAS28 ≤5,1) – 35,8 [13,4; 64,2] и 3222,6 [1881,0; 5671,9] соответственно (p&lt;0,05). Среди пациентов, высокопозитивных по IgM РФ, регистрировался более высокий уровень провоспалительных цитокинов: ИЛ1β, ИЛ2, ИЛ6, ИЛ12, ИЛ15, интерферона γ, фактора некроза опухоли α; хемокина – моноцитарного хемотаксического белка 1 и факторов роста: ИЛ7 и васкулоэндотелиального фактора роста– 4,8 [2,8; 19,3], 23,0 [7,1; 55,8], 64,2 [41,6; 170,5], 52,2 [30,9; 126,9], 2,4 [0,2; 11,2], 210,8 [119,9; 584,2], 90,7 [42,7;307,9], 57,5 [26,1; 93,8], 54,9 [37,1; 123,7], 143,3 [70,6; 249,6], по сравнению с негативными/низкопозитивными по IgM РФ пациентами: 2,3 [1,9; 3,1], 4,9 [2,9; 16,8], 24,9 [20,4; 45,4], 25,6 [19,9; 57,1], 0,2 [0,01; 1,65], 94,4 [86,3; 138,9], 37,3 [23,6; 47,7], 20,9 [12,3; 33,9], 32,6 [28,1; 37,8], 74,2 [53,5; 147,6] соответственно (p&lt;0,05).</p></sec><sec><title>Заключение</title><p>Заключение. Пациенты с ранним РА имеют достоверные различия показателей цитокинового профиля в зависимости от активности заболевания и уровня аутоантител в сыворотке крови.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective: to assess the association of cytokine profile measures with disease activity, autoantibody levels, and joint destructive changes in patients with early rheumatoid arthritis (RA).</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. Forty-five patients, including 35 women, with early RA were examined. Their median age was 53.5 [46; 59.5] years; the duration of the disease – 7.0 [4.0; 11.5] months; DAS28 – 5.8 [4.9; 6.4]; 91 and 96% of the patents were positive for rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies, respectively. Serum cytokine concentrations were estimated using the xMAP multiplex technology. The modified Sharp method was employed to quantify radiographic changes.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. A group of 30 patients with high disease activity (DAS28 &gt;5.1) had higher levels of interleukin (IL)-6 (62.3 [36.1; 127.5] pg/ml) and IP-10 (6367.8 [3682.7; 10691.3] pg/ml than 15 patients with moderate/low disease activity (DAS28 ≤5.1) (35.8 [13.4; 64.2] and 3222.6 [1881.0; 5671.9] pg/ml, respectively, p &lt; 0.05). The patients highly positive for IgM RF had higher levels (pg/ml) of proinflammatory cytokines, such as IL-1β, IL-2, IL-6, IL-12, IL-15, interferon-γ, and tumor necrosis factor-α; the chemokine monocyte chemotactic protein-1 and the growth factors IL-7 and vascular endothelial growth factor (4.8 [2.8; 19.3], 23.0 [7.1; 55.8], 64.2 [41.6; 170.5], 52.2 [30.9; 126.9], 2.4 [0.2; 11.2], 210.8 [119.9; 584.2], 90.7 [42.7; 307/9], 57.5 [26.1; 93.8], 54.9 [37.1; 123.7], and 143.3 [70.6; 249.6] pg/ml) than those who were negative/lowly positive for IgM RF (2.3 [1.9; 3.1], 4.9 [2.9; 16.8], 24.9 [20.4; 45.4], 25.6 [19.9; 57.1], 0.2 [0.01; 1.65], 94.4 [86.3; 138.9], 37.3 [23.6; 47.7], 20.9 [12.3; 33.9], 32.6 [28.1; 37.8], 74.2 [53.5; 147.6], respectively (p &lt; 0.05)).</p></sec><sec><title>Conclusion</title><p>Conclusion. There are significant differences in cytokine profile measures in patients with early RA in relation to disease activity and serum autoantibody levels.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ранний ревматоидный артрит</kwd><kwd>аутоантитела</kwd><kwd>деструкция суставов</kwd><kwd>цитокиновый профиль</kwd></kwd-group><kwd-group xml:lang="en"><kwd>early rheumatoid arthritis</kwd><kwd>autoantibodies</kwd><kwd>joint destruction</kwd><kwd>cytokine profile</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит В кн.: Ревматология: Национальное руководство. Под ред. ЕЛ Насонова, ВА Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 290–331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova A, editors. Revmatologiya: Natsional'noe rukovodstvo [Rheumatology: National guidelines]. Moscow: GEOTAR-Media; 2008. P. 290–331].</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит В кн.: Ревматология: Национальное руководство. Под ред. ЕЛ Насонова, ВА Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 290–331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova A, editors. Revmatologiya: Natsional'noe rukovodstvo [Rheumatology: National guidelines]. Moscow: GEOTAR-Media; 2008. P. 290–331].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010 [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical guidelines]. Moscow: GEOTAR-Media; 2010].</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010 [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical guidelines]. Moscow: GEOTAR-Media; 2010].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Choy E. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:510–8.</mixed-citation><mixed-citation xml:lang="en">Choy E. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:510–8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Firestein G. Evolving concepts of rheumatoid arthritis. Nature. 2003;344:907–16. doi: 10.1038/nature01661</mixed-citation><mixed-citation xml:lang="en">Firestein G. Evolving concepts of rheumatoid arthritis. Nature. 2003;344:907–16. doi: 10.1038/nature01661</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">McInnes I, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42. doi: 10.1038/nri2094</mixed-citation><mixed-citation xml:lang="en">McInnes I, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42. doi: 10.1038/nri2094</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dayer J, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162(6):2163–8. doi: 10.1084/jem.162.6.2163</mixed-citation><mixed-citation xml:lang="en">Dayer J, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162(6):2163–8. doi: 10.1084/jem.162.6.2163</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(26):1717–25. doi: 10.1056/NEJM199606273342607</mixed-citation><mixed-citation xml:lang="en">Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(26):1717–25. doi: 10.1056/NEJM199606273342607</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol. 2004:13(4):193–222. doi: 10.1111/j.0906-6705.2004.00205.x</mixed-citation><mixed-citation xml:lang="en">Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol. 2004:13(4):193–222. doi: 10.1111/j.0906-6705.2004.00205.x</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol. 2003 SepOct;21(5):392–7. doi: 10.1016/j.clindermatol.2003.08.015</mixed-citation><mixed-citation xml:lang="en">Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol. 2003 SepOct;21(5):392–7. doi: 10.1016/j.clindermatol.2003.08.015</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Taha A, Grant V, Kelly R. Urinalysis for interleukin-8 in the noninvasive diagnosis of acute and chronic inflammatory diseases. Postgrad Med J. 2003;79(929):159–63. doi: 10.1136/pmj.79.929.159</mixed-citation><mixed-citation xml:lang="en">Taha A, Grant V, Kelly R. Urinalysis for interleukin-8 in the noninvasive diagnosis of acute and chronic inflammatory diseases. Postgrad Med J. 2003;79(929):159–63. doi: 10.1136/pmj.79.929.159</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Rothe L, Collin-Osdoby P, Chen Y, et al. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology. 1998;139(10):4353–63.</mixed-citation><mixed-citation xml:lang="en">Rothe L, Collin-Osdoby P, Chen Y, et al. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology. 1998;139(10):4353–63.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Romano M, Polentarutti N, Fruscella P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6;315–25. doi: 10.1016/S1074-7613(00)80334-9</mixed-citation><mixed-citation xml:lang="en">Romano M, Polentarutti N, Fruscella P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6;315–25. doi: 10.1016/S1074-7613(00)80334-9</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lally F, Smith E, Filer A, et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum. 2005;52:3460–9. doi: 10.1002/art.21394</mixed-citation><mixed-citation xml:lang="en">Lally F, Smith E, Filer A, et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum. 2005;52:3460–9. doi: 10.1002/art.21394</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74. doi: 10.1016/S0140-6736(07)60784-3</mixed-citation><mixed-citation xml:lang="en">Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74. doi: 10.1016/S0140-6736(07)60784-3</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002;4(Suppl. 3):81–90. doi: 10.1186/ar575</mixed-citation><mixed-citation xml:lang="en">Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002;4(Suppl. 3):81–90. doi: 10.1186/ar575</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther. 2007;9:203. doi: 10.1186/ar2110</mixed-citation><mixed-citation xml:lang="en">Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther. 2007;9:203. doi: 10.1186/ar2110</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kudo O, Sabokbar A, Pocock A, et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1–7. doi: 10.1016/S8756- 3282(02)00915-8</mixed-citation><mixed-citation xml:lang="en">Kudo O, Sabokbar A, Pocock A, et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1–7. doi: 10.1016/S8756- 3282(02)00915-8</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48:1521–9. doi: 10.1002/art.11143</mixed-citation><mixed-citation xml:lang="en">Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48:1521–9. doi: 10.1002/art.11143</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307–10. doi: 10.1016/S0092-8674(00)81109-5</mixed-citation><mixed-citation xml:lang="en">Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307–10. doi: 10.1016/S0092-8674(00)81109-5</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. doi: 10.1146/annurev.immunol.14.1.397</mixed-citation><mixed-citation xml:lang="en">Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. doi: 10.1146/annurev.immunol.14.1.397</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8. doi: 10.1136/ard.2010.138461</mixed-citation><mixed-citation xml:lang="en">Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8. doi: 10.1136/ard.2010.138461</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117–25 [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):117–25 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117–25 [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):117–25 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Heijde D, Boers M, Lassere M. Methodological issues in radiographic scoring methods in rheumatoid arthritis. J Rheumatol. 1999;26:726–30.</mixed-citation><mixed-citation xml:lang="en">Van der Heijde D, Boers M, Lassere M. Methodological issues in radiographic scoring methods in rheumatoid arthritis. J Rheumatol. 1999;26:726–30.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Alex P, Szodoray P, Knowlton N, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exper Rheumatol. 2007;25:584–92.</mixed-citation><mixed-citation xml:lang="en">Alex P, Szodoray P, Knowlton N, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exper Rheumatol. 2007;25:584–92.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hueber W, Tomooka B, Zhao X, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis. 2007;66;712–9. doi: 10.1136/ard.2006.054924</mixed-citation><mixed-citation xml:lang="en">Hueber W, Tomooka B, Zhao X, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis. 2007;66;712–9. doi: 10.1136/ard.2006.054924</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Yellin M, Paliienko I Balanescu A, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of mdx-1100, a fully human anti-cxcl10 monoclonal antibody, in combination with methotrexate in patients with rheumatoidarthritis. Arthritis Rheum. 2012;64:1730–9. doi: 10.1002/art.34330</mixed-citation><mixed-citation xml:lang="en">Yellin M, Paliienko I Balanescu A, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of mdx-1100, a fully human anti-cxcl10 monoclonal antibody, in combination with methotrexate in patients with rheumatoidarthritis. Arthritis Rheum. 2012;64:1730–9. doi: 10.1002/art.34330</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Astry B, Venkatesha S, Moudgil K. Temporal cytokine expression and the target organ attributes unravel novel aspects of autoimmune arthritis. Indian J Med Res. 2013;138:717–31.</mixed-citation><mixed-citation xml:lang="en">Astry B, Venkatesha S, Moudgil K. Temporal cytokine expression and the target organ attributes unravel novel aspects of autoimmune arthritis. Indian J Med Res. 2013;138:717–31.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев ДЕ. Ангиогенез при ревматоидном артрите. Вестник РАМН. 2003;7:47–51 [Karateev DE. Angiogenesis in rheumatoid arthritis. Vestnik RAMN. 2003;7:47–51 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Каратеев ДЕ. Ангиогенез при ревматоидном артрите. Вестник РАМН. 2003;7:47–51 [Karateev DE. Angiogenesis in rheumatoid arthritis. Vestnik RAMN. 2003;7:47–51 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Marrelli A, Cipriani P, Liakouli V, et al. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev. 2011;10:595–8. doi: 10.1016/j.autrev.2011.04.020</mixed-citation><mixed-citation xml:lang="en">Marrelli A, Cipriani P, Liakouli V, et al. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev. 2011;10:595–8. doi: 10.1016/j.autrev.2011.04.020</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Paleolog EM. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol. 2009;90:249–61. doi: 10.1111/j.1365-2613.2009.00640.x</mixed-citation><mixed-citation xml:lang="en">Paleolog EM. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol. 2009;90:249–61. doi: 10.1111/j.1365-2613.2009.00640.x</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Lu Q, Lu S, Gao X, et al. Norisoboldine, an alkaloid compound isolated from Radix linderae, inhibits synovial angiogenesis in adjuvant-induced arthritis rats by moderating Notch1 pathwayrelated endothelial tip cell phenotype. Exp Biol Med (Maywood). 2012;237:919–32. doi: 10.1258/ebm.2012.011416</mixed-citation><mixed-citation xml:lang="en">Lu Q, Lu S, Gao X, et al. Norisoboldine, an alkaloid compound isolated from Radix linderae, inhibits synovial angiogenesis in adjuvant-induced arthritis rats by moderating Notch1 pathwayrelated endothelial tip cell phenotype. Exp Biol Med (Maywood). 2012;237:919–32. doi: 10.1258/ebm.2012.011416</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Tanaka K, Morii T, Weissbach L, et al. Treatment of collageninduced arthritis with recombinant plasminogen-related protein B: a novel inhibitor of angiogenesis. J Orthop Sci. 2011;16:443–50. doi: 10.1007/s00776-011-0091-x</mixed-citation><mixed-citation xml:lang="en">Tanaka K, Morii T, Weissbach L, et al. Treatment of collageninduced arthritis with recombinant plasminogen-related protein B: a novel inhibitor of angiogenesis. J Orthop Sci. 2011;16:443–50. doi: 10.1007/s00776-011-0091-x</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Yoo SA, Bae DG, Ryoo JW, et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNFalpha and IL-6 by human monocytes. J Immunol. 2005;174:5846–55. doi: 10.4049/jimmunol.174.9.5846</mixed-citation><mixed-citation xml:lang="en">Yoo SA, Bae DG, Ryoo JW, et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNFalpha and IL-6 by human monocytes. J Immunol. 2005;174:5846–55. doi: 10.4049/jimmunol.174.9.5846</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Fong GH. Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis. 2008;11:121–40. doi: 10.1007/s10456-008-9107-3</mixed-citation><mixed-citation xml:lang="en">Fong GH. Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis. 2008;11:121–40. doi: 10.1007/s10456-008-9107-3</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Maruotti N, Cantatore FP, Crivellato E, et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol. 2006;21:557–66.</mixed-citation><mixed-citation xml:lang="en">Maruotti N, Cantatore FP, Crivellato E, et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol. 2006;21:557–66.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Ballara S, Taylor P, Reusch P, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 2001;44:2055–64. doi: 10.1002/1529-0131(200109)44:9&lt;2055::AID-ART355&gt;3.0.CO;2-2</mixed-citation><mixed-citation xml:lang="en">Ballara S, Taylor P, Reusch P, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 2001;44:2055–64. doi: 10.1002/1529-0131(200109)44:9&lt;2055::AID-ART355&gt;3.0.CO;2-2</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Clavel G, Bessis N, Lemeiter D. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol. 2007;124:158–64. doi: 10.1016/j.clim.2007.04.014</mixed-citation><mixed-citation xml:lang="en">Clavel G, Bessis N, Lemeiter D. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol. 2007;124:158–64. doi: 10.1016/j.clim.2007.04.014</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Knudsen L, Ostergaard M, Baslund B, et al. Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scand J Rheumatol. 2006;35:489–95. doi: 10.1080/03009740600904300</mixed-citation><mixed-citation xml:lang="en">Knudsen L, Ostergaard M, Baslund B, et al. Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scand J Rheumatol. 2006;35:489–95. doi: 10.1080/03009740600904300</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Kurosaka D, Hirai K, Nishioka M, et. al. Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol. 2010;37:6. doi: 10.3899/jrheum.090941</mixed-citation><mixed-citation xml:lang="en">Kurosaka D, Hirai K, Nishioka M, et. al. Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol. 2010;37:6. doi: 10.3899/jrheum.090941</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Kokkonen H, Soderstrom I, Rocklov J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62:383–91. doi: 10.1002/art.27186</mixed-citation><mixed-citation xml:lang="en">Kokkonen H, Soderstrom I, Rocklov J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62:383–91. doi: 10.1002/art.27186</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Sokolove J, Bromberg R, Deane K, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012;7(5):e35296. doi: 10.1371/journal.pone.0035296</mixed-citation><mixed-citation xml:lang="en">Sokolove J, Bromberg R, Deane K, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012;7(5):e35296. doi: 10.1371/journal.pone.0035296</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Eastman PS, Manning WC, Qureshi F, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal. 2012;70:415–24. doi: 10.1016/j.jpba.2012.06.003</mixed-citation><mixed-citation xml:lang="en">Eastman PS, Manning WC, Qureshi F, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal. 2012;70:415–24. doi: 10.1016/j.jpba.2012.06.003</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Raza K, Falciani F, Curnow S, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005;7(4):784–95. doi: 10.1186/ar1733</mixed-citation><mixed-citation xml:lang="en">Raza K, Falciani F, Curnow S, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005;7(4):784–95. doi: 10.1186/ar1733</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
